BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Alopecia Areata readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Alopecia Areata\, fro
 m ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05723198-98@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Olumiant (baricitinib): Phase 3 readout est. (NCT05723198)
DESCRIPTION:Olumiant (baricitinib)\, phase 3\, Alopecia Areata.\nStudy: A S
 tudy of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Y
 ears of Age With Alopecia Areata\nEstimated primary completion: March 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/baricitinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05723198
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07023302-12@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT07023302)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Alopecia Areata.\nStudy: A St
 udy to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Ad
 ult and Adolescent Participants in Japan With Alopecia Areata\nEstimated p
 rimary completion: February 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/upadacitinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07023302
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06012240-12@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT06012240)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Alopecia Areata.\nStudy: A St
 udy to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Ad
 ult and Adolescent Participants With Severe Alopecia Areata\nEstimated pri
 mary completion: April 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/upadacitinib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06012240
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07772492-12@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20320331
DTEND;VALUE=DATE:20320401
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT07772492)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Alopecia Areata.\nStudy: A St
 udy to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric 
 Participants With Alopecia Areata\nEstimated primary completion: March 203
 2. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/upadacitinib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07772492
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
